FDAsafety guidance66% confidence
eCTD Submission Standards for eCTD v3.2.2 and Regional M1
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Biocon Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Diabetes · DPP-4 Inhibitor
- Sub-indication
- General
Related signal: FDA Submission Update for Sitagliptin by Biocon Pharma